Cutaneous T-Cell Lymphoma (CTCL) Withdrawn Phase 2 Trials for Curcumin (DB11672)

Also known as: Cutaneous T Cell Lymphoma (CTCL) / Cutaneous T Cell Lymphomas (CTCL) / Cutaneous T-Cell Lymphoma / Cutaneous T Cell Lymphoma / Cutaneous T-Cell Lymphomas / CTCL / Primary cutaneous T-cell lymphoma (morphologic abnormality) / Cutaneous T-cell lymphoma (morphologic abnormality) / Primary cutaneous T-cell lymphoma (disorder) / Lymphoma, T-Cell, Cutaneous

IndicationStatusPhase
DBCOND0071861 (Cutaneous T-Cell Lymphoma (CTCL))Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00969085Trial of Curcumin in Cutaneous T-cell Lymphoma PatientsTreatment